Search This Blog

Thursday, March 26, 2026

EMA validates Nuvation Bio’s taletrectinib MAA for advanced ROS1-positive non-small cell lung cancer

 European Medicines Agency validates Nuvation Bio’s taletrectinib MAA for advanced ROS1-positive non-small cell lung cancer 

https://finviz.com/quote.ashx?t=NUVB&p=d

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.